Peer-influenced content. Sources you trust. No registration required. This is HCN.

Practical Pain ManagementNerivio Gets FDA Nod for Use in Migraine Prevention

A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 248 participants was used to gain FDA approval. The device activates peripheral nerves using painless, remote electrical neuromodulation, inducing a conditioned pain modulation response. The device, which is worn on the upper arm, is controlled by a smartphone app that provides users with additional benefits such as the ability to customize their treatments, receive reminders for preventive treatments, track the patterns of their headaches, and, if desired, share this data with their physicians.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form